Sign In
Buy ELV
$388.50
-2.77 (-0.708%)
At Close: Jun 18, 2026
Elevance Health to Hold Conference Call and Webcast to Discuss Third Quarter 2025 Results on October 21
04:30pm, Monday, 29'th Sep 2025
INDIANAPOLIS--(BUSINESS WIRE)--Elevance Health (NYSE: ELV) will release third quarter 2025 financial results on October 21, 2025, at 6:00 a.m. Eastern Daylight Time (“EDT”). Management will review
Elevance Health: Undervalued Defensive Giant With Long-Term Upside
08:40am, Friday, 26'th Sep 2025
Elevance Health is significantly undervalued, trading at a 41% discount to industry peers, despite strong revenue growth and a 2.11% dividend yield. ELV's recent selloff was triggered by bottom-line c
Northwest Middle School Unveils New Weight Room in Partnership with Elevance Health and Impact Fitness Foundation
08:00am, Wednesday, 24'th Sep 2025
INDIANAPOLIS--(BUSINESS WIRE)--Indianapolis Public Schools' Northwest Middle School today celebrated the unveiling of its newly transformed weight room, a project made possible through a partnership w
Elevance Health Shrinks to Grow Stronger: From Part D to Plan B?
10:31am, Friday, 12'th Sep 2025
ELV exits Part D and trims Medicare Advantage markets, betting on stronger-margin plans to protect profitability.
New Strong Sell Stocks for September 11th
06:21am, Thursday, 11'th Sep 2025
REFI, ELV and TAP have been added to the Zacks Rank #5 (Strong Sell) List on September 11, 2025.
AM Best Assigns Issue Credit Ratings to Elevance Health, Inc. New Senior Unsecured Notes
05:25pm, Wednesday, 10'th Sep 2025
OLDWICK, N.J.--(BUSINESS WIRE)-- #insurance--AM Best has assigned a Long-Term Issue Credit Rating of “bbb+” (Good) to Elevance Health Inc.'s (Elevance Health) (headquartered in Indianapolis, IN) n
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Elevance (ELV) To Contact Him Directly To Discuss Their Options If you are a long-term sto
Elevance Health: Keep It Simple And Buy This Great Business At A Low Valuation
04:53pm, Monday, 08'th Sep 2025
ELV stands out as an outperformer due to strong historical performance, capital returns, and a robust balance sheet. Sector tailwinds and AI-driven efficiency gains present attractive long-term opport
Elevance Health price target raised to $373 from $327 at Barclays
06:23am, Thursday, 04'th Sep 2025
Barclays raised the firm's price target on Elevance Health to $373 from $327 and keeps an Overweight rating on the shares. The firm adjusted estimates and targets in the managed care and healthcare fa
Elevance Health Foundation Awards $6.5 Million to Strengthen Maternal and Infant Health Across the United States
08:00am, Wednesday, 03'rd Sep 2025
INDIANAPOLIS--(BUSINESS WIRE)--The Elevance Health Foundation has awarded 29 new grants totaling more than $6.5 million to support maternal and infant health programs across the country. The funding w
Top 15 High-Growth Dividend Stocks For September 2025
06:16am, Monday, 01'st Sep 2025
My Top 15 high-growth dividend stocks for September 2025 are collectively 32% undervalued and offer a 1.43% yield with 21.57% five-year dividend growth. The strategy's five-year annualized return is 1
Is ELV's Push Beyond Insurance a Blueprint for the Healthcare Future?
01:45pm, Friday, 29'th Aug 2025
Elevance Health expands beyond insurance into primary care, digital health and pharmacy services, aiming to reshape healthcare delivery.
CVS vs. ELV: Which Healthcare Titan Is the Stronger Investment Today?
10:25am, Wednesday, 27'th Aug 2025
CVS Health advances with Aetna margin recovery, digital investments and cost savings, making it the stronger healthcare bet over Elevance.
Can Elevance Health's Value-Based Care Strategy Fuel Long-Term Growth?
01:55pm, Friday, 22'nd Aug 2025
ELV's focus on value-based care, Carelon integration and CareBridge acquisition drives membership and revenue growth.
Elevance Health - Piggy Bank Or Headache?
05:46pm, Thursday, 21'st Aug 2025
Elevance and peers face earnings pressure from rising medical costs, driven by deferred care, expensive drugs, and persistent medical inflation. The segment has re-rated, and now offers good value. In
